Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 123 results

Author Title Type [ Year

]

2019

Patel A, Namn Y, Shah SL, Scherl E, Wan DW. 2019. Takotsubo cardiomyopathy after an upper and lower endoscopy: a case report and review of the literature.. J Med Case Rep. 13(1):81.

Qazi T, Verma R, Hamilton MJ, Kaplan ER, Redline S, Burakoff R. 2019. The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn's Disease.. Inflamm Bowel Dis. 25(6):1044-1053.

Choi AJ, Atteberry P, Lukin DJ. 2019. Vaccination in the Elderly and IBD.. Curr Treat Options Gastroenterol. 17(4):492-505.

2018

Zhang S, Fu J, Dogan B, Scherl EJ, Simpson KW. 2018. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.. J Antibiot (Tokyo). 71(11):950-961.

Borges LF, Jagadeesan V, Goldberg H, Gavini S, Lo W-K, Burakoff R, Feldman N, Chan WW. 2018. Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis.. J Neurogastroenterol Motil. 24(3):395-402.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al.. 2018. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.

Dogan B, Belcher-Timme HFacey, Dogan EI, Jiang Z-D, Dupont HL, Snyder N, Yang S, Chandler B, Scherl EJ, Simpson KW. 2018. Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.. FEMS Microbiol Lett. 365(22)

Kumar A, Kim M, Lukin DJ. 2018. Helicobacter pylori is associated with increased risk of serrated colonic polyps: Analysis of serrated polyp risk factors.. Indian J Gastroenterol. 37(3):235-242.

Cohen-Mekelburg S, Rosenblatt R, Gold S, Burakoff R, Waljee AK, Saini S, Schackman BR, Scherl E, Crawford C. 2018. The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients.. J Crohns Colitis. 12(9):1030-1035.

Castellanos JG, Woo V, Viladomiu M, Putzel G, Lima S, Diehl GE, Marderstein AR, Gandara J, Perez AR, Withers DR et al.. 2018. Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.. Immunity. 49(6):1077-1089.e5.

Ghosh G, Jacob V, Wan D. 2018. Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.. Clin Gastroenterol Hepatol. 16(4):e41-e42.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al.. 2018. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.

Dogan B, Fu J, Zhang S, Scherl EJ, Simpson KW. 2018. Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.. J Antibiot (Tokyo). 71(5):485-494.

Battat R, Duijvestein M, Casteele NVande, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M et al.. 2018. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol.

Cohen-Mekelburg S, Tafesh Z, Coburn E, Weg R, Malik N, Webb C, Hammad H, Scherl E, Bosworth BP. 2018. Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.. Dig Dis Sci. 63(9):2439-2444.

Gold SL, Magro C, Scherl E. 2018. A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.. Gastroenterology. 155(4):981-982.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al.. 2018. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.

2017

Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. 2017. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.

Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A et al.. 2017. IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.. Sci Transl Med. 9(376)

J Blander M, Longman RS, Iliev ID, Sonnenberg GF, Artis D. 2017. Regulation of inflammation by microbiota interactions with the host.. Nat Immunol. 18(8):851-860.

Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al.. 2017. Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.

Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al.. 2017. Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.

2016

DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. 2016. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.. Curr Gastroenterol Rep. 18(3):13.

DeFilippis EM, Tabani S, Warren RU, Christos PJ, Scherl EJ. 2016. Exercise and Self-Reported Limitations in Patients with Inflammatory Bowel Disease.. Dig Dis Sci. 61(1):215-20.

Kivolowitz C, Abdulhamid A, Victorio D, Castellanos J, Simpson K, Scherl E, Longman R. 2016. O-006 Expansion of Immunologically-Relevant E. Coli in the Intestinal Microbiota of Patients with IBD-Associated Spondyloarthritis Promotes Mucosal RORgt-Dependent Immunity.. Inflamm Bowel Dis. 22 Suppl 1:S3.